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We prepared methyl 2,.5-dihydroxycinnamate s a stable analogue of erbstatin, a tyrosine kinase inhibitor. This analogue was about 4 times more 
stable than erbstatin in calf serum. It inhibited epidermal growth factor receptor-associated tyrosine kinase in vitro with an XC, of 0.15 pg/ml. 
It also inhibited in situ autophosphorylatio~ of epidermal growth factor receptor in A43I cells. Methyl 2,5-dihy~oxycinn~ate was shown to 
delay the S-phase induction by epidermal growth factor in quiescent normal rat kidney cells, without affecting the total amount of DNA synthesis, 
The effect of erbstatin on S-phase induction was smaller, possibly because of its shorter life time. 
Erbstatin; Epidermal growth factor; DNA synthesis; Cell cycle; (Normal rat kidney cell) 
1. INTRODUCTION 
Erbstatin, isolated as an inhibitor of tyrosine kinase 
associated with the epidermal growth factor (EGF) 
receptor [ 11, inhibits autophosphorylation and inter- 
nalization of EGF receptors in cultured A431 cells 121, 
and halts the growth of human breast cancer cell line 
MCF-7 in nude mice [3]. However, erbstatin is easily in- 
activated in calf serum [4], and more stable analogues 
of erbstatin have been looked for. Previously, we syn- 
thesized various erbstatin analogues and tested them for 
their inhibitory activity against tyrosine kinase [S]. 
Among them only 2,5-dihydroxycinnamic acid has, in- 
stead of the N-formyl moiety, the carboxylic acid moie- 
ty, which would be more stable. This analogue inhibits 
tyrosine kinase in vitro, but its in situ or in vivo activity 
is not expected, because, being a polar molecule, it 
would be difficult to penetrate into the cells. Therefore, 
we synthesized methyl 2,5dihydroxycinnamate to 
reduce the polarity of the molecule and examined its ef- 
fectiveness as an inhibitor. 
As the effect of tyrosine kinase inhibitors on the cell 
cycle has not been assessed, we also examined this point 
and found that these tyrosine kinase inhibitors delay 
EGF-induced DNA synthesis in quiescent NRK cells. 
2. MATERIALS AND METHODS 
2.1. Materials 
Erbstatin was isolated from Streptomyces MH435-hF3 as described 
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previously [I], The synthetic peptide RR-SRC and EGF were purchas- 
ed from the Peptide Institute, Osaka, and Takara Shuzo, Kyoto, 
respectively. Monoclonal antibody for EGF receptor came from 
Transformation Research Inc. [y-“P]ATP (4.64 Ci/mmol), and 
[3H]thymidine (47 Ci/mmol) were products of Amersham. 
~3zP]Phosphate was purchased from New England Nuclear. The A431 
cell line was a gift of Dr S. Kawai, Institute of Medical Science, 
University of Tokyo. The NRK-49F cells (ATCC CRL-1570) were ob- 
tained through Flow Laboratories, Inc. 
2.2. Stability of chemicals in serum 
For the assay of the stability of inhibitors in serum, a given in- 
hibitor (lOfig) was added to 0.1 ml calf serum (Gibco) and the mixture 
shaken vigorously at 37°C. After the incubation 0.1 ml of ethanol was 
added to the mixture; which was then left on ice for 30 min and cen- 
trifuged at 13000 rpm. The supernatant was applied to an HPLC 
(nucleosil $18, 4.6 0 x 250 mm) for quantitative analysis. 
2.3. Cell culture 
A431 and NRK cells were grown in a 5% CO2 atmosphere in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
5% and 10% calf serum, respectively. 
2.4. Tyrosine kinase assay 
For the in vitro tyrosine kinase assay [a] the reaction mixture con- 
taining synthetic peptide (RR-SRC), [T-~*P]ATP, ECF, and the mem- 
brane fraction of A431 cetls with or without inhibitor was incubated 
at 0°C for 30 min in 20 mM Hepes buffer (pH 7.2). The reaction was 
stopped by the addition of 10% trichloroacetic acid. Then, the mix- 
ture was centrifuged (1300 rpm, 5 min), and the supernatant was ap- 
plied to a piece of P81 phosphocellulose paper. The paper was then 
washed in 30% acetic acid for 15 min. 3 times in 15670 acetic acid, rins- 
ed in acetone, and counted for radioactivity. 
For the in situ tyrosine kinase assay, A431 cells (5 x Id) were 
grown in 35-mm dishes for 18 h before use. The cells were then wash- 
ed and labeled for 4 h with 32Pi n 1 ml of phosphate-free medium. 
Then, the desired inhibitor and/or EGF were/was added. After 20 
min, the cells were extracted with radio-immune precipitation (RIPA) 
buffer. The cell extract was incubated for 2 h at 4°C with monoclonal 
anti-EGF receptor antibody, and then a suspension of Staphylococcus 
aareus Cowan I was added. The mixture was allowed to stand at 4°C 
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Fig.1. Synthesis of methyl 2,5dihydroxycinnamate. 
overnight. The bacterial cells adsorbing the immune complexes were 
then washed with RIPA buffer, suspended in electrophoresis loading 
buffer, boiled for 5 min, and centrifuged at 15 000 x g for 1 min. The 
supernatant was electrophoresed on an SDS-polyacrylamide gel. 
2.5. PH]Thymidine incorporation 
NRK cells (4 x 16) were plated in a l6-mm glassware dish and 
cultured in 1 ml of DMEM containing 10% calf serum for 60 h. Dur- 
ing this period the cells became quiescent by density-dependent i hibi- 
tion. Then, the cells were washed twice with 0.5 ml of serum-free 
DMEM and given 1 ml of serum-free DMEM containing inhibitor 
and/or 100 ng/ml of EGF. After incubation for indicated periods, the 
cells were washed twice with 0.5 ml of Dulbecco’s phosphate-buffered 
saline, followed by the addition of 1 ml of serum-free DMEM con- 
taining 1 &i/ml of [‘Hlthymidine. After 1 h the cells were washed 
twice with 0.5 ml of Dulbecco’s phosphate-buffered saline, and 0.5 ml 
of cold 10% trichloroacetic acid (TCA) was added. After incubation 
for 10 min at 4”C, the cells were further washed twice with 0.5 ml of 
10% TCA. Then, they were solubilized by 0.5 ml of 0.5 N NaOH and 
an aliquot was counted for radioactivity in a liquid scintillation 
counter. 
3. RESULTS 
Synthesis of methyl 2,5-dihydroxycinnamate is 
shown in fig. 1. 2,5Dihydroxybenzaldehyde (4.3 g) and 
methyl(triphenylphosphoranilidene) acetate (11.6 g) 
were mixed in 10 ml of tetrahydrofuran and 120 ml of 
toluene and stirred for 30 min at 60°C. Then the mix- 
ture was evaporated and applied onto a silica gel col- 
umn (305 g, CHCWMeOH 20: 1) to give 5.7 g of yellow 
flakes. The crude product was further purified by 
LH-20 column chromatography with MeOH to give 
Oi 
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Fig.2. Stability of methyl 2,5_dihydroxycinnamate in calf serum. 
Methyl 2,5hydroxycinnamate (0) or erbstatin (e) was incubated of 
calf serum for the indicated periods. The recovery of each inhibitor 
was determined by HPLC. 
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Fig.3. Inhibition of EGF receptor-associated tyrosine kinase by 
methyl 2,5-dihydroxycinnamate. The reaction mixture was incubated 
with methyl 2,5_dihydroxycinnamate (0) or erbstatin (0) for 30 min. 
4.86 g of methyl 2,5_dihydroxycinnamate as a yellow 
powder. The structure was confirmed by proton NMR 
spectroscopy. 
As shown in fig.2 methyl 2,5-dihydroxycinnamate 
was about 4 times more stable than erbstatin in calf 
serum. Erbstatin disappeared completely by 30 min, 
while methyl 2,5-dihydroxycinnamate was still 
recovered in appreciable amount even after a 60-min in- 
cubation. 
Methyl 2,5-dihydroxycinnamate inhibited EGF 
receptor tyrosine kinase in vitro with an 1% of 0.15 
pg/ml, which is equivalent o the activity of erbstatin, 
as shown in fig.3. At higher concentrations, it inhibited 
tyrosine kinase more strongly than did erbstatin. 
Lineweaver-Burk plotting showed that it inhibits EGF 
receptor kinase competitively with the peptide and non- 
Fig.4. Inhibition by methyl 2,5-hydroxycinnamate of EGF receptor 
autophosnhorvlation in cultured A431 cells. The cells were orein- 
cubated with 100 fig (lane I), 50 fig (2), 25 pg (3), or 0,4g (4) of in- 
hibitor for 1 h; and then 0.5 &ml of EGF was added and incubation , _ 
continued for 20 min. For lane 5, no inhibitor or EGF was added to 
the cells. 
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Fig.5. Inhibition of EGF-induced DNA synthesis by tyrosine kinase 
inhibitors. Quiescent NRK cells were incubated without additives (0) 
or with EGF (o), EGF and 12.5 /g/ml of erbstatin (A), or EGF and 
12.5 fig/ml of methyl 2,5dihydroxycinnamate (v). Details are 
described in section 2. 
competitively with ATP (data not shown), as is the case 
for erbstatin [7]. As shown in fig.4, the methyl ester 
derivative inhibited EGF receptor autophosphorylation 
in cultured A431 cells at 25-lOOpg/ml. This in situ ac- 
tivity of methyl 2,5_dihydroxycinnamate is comparable 
to that of erbstatin [2]. The decrease in autophos- 
phorylation is not due to the inhibition of EGF binding, 
since we confirmed that the inhibitor did not affect 
EGF-receptor binding in A431 cells at 100 pg/ml. 
In quiescent NRK cells, addition of EGF began to in- 
duce DNA synthesis after 12 h, and the maximal effect 
was observed at 16 h, as shown in fig.5. Addition of 
12.5 pg/ml of erbstatin delayed the induction of DNA 
synthesis for about 3 h. Methyl 2,5-dihydroxycin- 
namate apparently delayed the DNA synthesis induc- 
tion by EGF for about 10 h. In both cases, the total 
amount of DNA synthesis did not decrease. Similar 
results were obtained in 3 repeated experiments. 
4. DISCUSSION 
Methyl 2,5-dihydroxycinnamate was shown to be 
more stable in serum than erbstatin, without losing its 
enzyme inhibition activity. In addition, the analogue is 
considered to penetrate into the cells, since it inhibits in 
situ autophosphorylation of the EGF receptor. Erb- 
statin and methyl 2,5_dihydroxycinnamate delayed the 
induced DNA synthesis at 12.5 pg/ml at which concen- 
tration the EGF-induced DNA synthesis was delayed 
for about 3 h by erbstatin and for about 10 h by methyl 
2,5_dihydroxycinnamate. Neither was effective at 3 
fig/ml, and at 50 pg/ml they reduced the total amount 
of DNA synthesis. For in situ inhibition of tyrosine 
kinase higher concentration (25-50 ,ug/ml) of methyl 
2,5_dihydroxycinnamate was required. It would be 
because its penetration into the cell is not sufficient 
within a short time incubation. Since methyl 2,5-dihy- 
droxycinnamate is about 4 times more stable than erb- 
statin, the difference noted in the delay until S-phase 
may be related to the stability of the inhibitor. 
Several enzyme inhibitors are known to affect S- 
phase induction by acting at the Gl-phase. W-13, a 
calmodulin blocker, inhibits S-phase induction acting at 
Gl and early S-phase [8,9]. Tunicamycin [lo], an in- 
hibitor of oligosaccharide synthesis, and bestatin [ 111, 
inhibiting aminopeptidase, were shown to inhibit DNA 
synthesis by acting at the Gl-phase. We have 
demonstrated that tyrosine kinase activity is essential 
for the S-phase induction by EGF in quiescent NRK 
cells. 
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